{"id":3945,"date":"2024-05-01T09:20:17","date_gmt":"2024-05-01T07:20:17","guid":{"rendered":"https:\/\/www.amyloidosisalliance.org\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/"},"modified":"2026-11-03T10:16:38","modified_gmt":"2026-11-03T09:16:38","slug":"neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht","status":"publish","type":"post","link":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/","title":{"rendered":"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Die in den Annals of Neurology ver\u00f6ffentlichte Studie mit dem Titel \u201eDisease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy\u201c beleuchtet die Wirksamkeit der Behandlungen der famili\u00e4ren Amyloid-Polyneuropathie (FAP). <br\/><br\/>Die FAP wird durch Mutationen im Transthyretin-Gen verursacht und f\u00fchrt zur Ablagerung toxischer Proteinklumpen im Nervengewebe, mit schwer beeintr\u00e4chtigenden Symptomen. Eine Heilung gibt es nicht, doch zu den Behandlungsm\u00f6glichkeiten geh\u00f6ren krankheitsmodifizierende Medikamente und die Lebertransplantation. <br\/><br\/>Die Forschenden analysierten die Daten von 201 FAP-Patienten \u00fcber drei Jahrzehnte und stellten deutliche Unterschiede im \u00dcberleben zwischen behandelten und unbehandelten Patienten fest.<br\/>Bemerkenswert ist, dass sch\u00e4tzungsweise fast alle behandelten #Patienten zehn Jahre nach Krankheitsbeginn noch lebten, gegen\u00fcber weniger als der H\u00e4lfte der unbehandelten Patienten. <br\/><br\/>Krankheitsmodifizierende Medikamente wie Onpattro, Tafamidis und Diflunisal zeigten vielversprechende Ergebnisse beim \u00dcberleben, unabh\u00e4ngig vom Alter bei Krankheitsbeginn.<br\/>Auch Patienten mit sp\u00e4t beginnender FAP \u00fcberlebten mit krankheitsmodifizierenden Medikamenten l\u00e4nger, was die Annahme in Frage stellt, die Lebertransplantation sei die wichtigste Behandlung der fr\u00fch beginnenden Formen. <br\/><br\/>W\u00e4hrend die Lebertransplantation das \u00dcberleben bei fr\u00fch beginnender FAP verl\u00e4ngerte, war ihre Wirkung bei sp\u00e4t beginnenden Formen weniger ausgepr\u00e4gt.<br\/>Die Studie unterstreicht die Bedeutung krankheitsmodifizierender Medikamente f\u00fcr ein besseres Langzeit\u00fcberleben von FAP-Patienten, unabh\u00e4ngig vom Alter bei Krankheitsbeginn oder von der Art der Symptome. <br\/><br\/>Die Analyse beschr\u00e4nkt sich allerdings auf ein einziges Zentrum, und weitere Studien sind n\u00f6tig, um diese Ergebnisse in anderen Bev\u00f6lkerungsgruppen und medizinischen Umfeldern zu best\u00e4tigen. <br\/><br\/>Den Artikel finden Sie hier <br\/><a href=\"https:\/\/urlr.me\/X1tHm\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-light-green-cyan-color\">https:\/\/urlr.me\/X1tHm<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eine Studie mit 201 Patienten \u00fcber drei Jahrzehnte legt nahe, dass krankheitsmodifizierende Therapien das \u00dcberleben bei ATTRv-Amyloidose mit Polyneuropathie verl\u00e4ngern.<\/p>\n","protected":false},"author":1,"featured_media":3946,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[],"class_list":["post-3945","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-de"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht<\/title>\n<meta name=\"description\" content=\"Eine Studie mit 201 Patienten \u00fcber drei Jahrzehnte legt nahe, dass krankheitsmodifizierende Therapien das \u00dcberleben bei ATTRv-Amyloidose mit Polyneuropathie verl\u00e4ngern.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht\" \/>\n<meta property=\"og:description\" content=\"Eine Studie mit 201 Patienten \u00fcber drei Jahrzehnte legt nahe, dass krankheitsmodifizierende Therapien das \u00dcberleben bei ATTRv-Amyloidose mit Polyneuropathie verl\u00e4ngern.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/\" \/>\n<meta property=\"og:site_name\" content=\"Amyloidosis Alliance\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmyloidosisAlliance\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-01T07:20:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-03T09:16:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"880\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:site\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/\"},\"author\":{\"name\":\"Amyloidosis Alliance\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#organization\"},\"headline\":\"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht\",\"datePublished\":\"2024-05-01T07:20:17+00:00\",\"dateModified\":\"2026-11-03T09:16:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\",\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/\",\"name\":\"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\",\"datePublished\":\"2024-05-01T07:20:17+00:00\",\"dateModified\":\"2026-11-03T09:16:38+00:00\",\"description\":\"Eine Studie mit 201 Patienten \u00fcber drei Jahrzehnte legt nahe, dass krankheitsmodifizierende Therapien das \u00dcberleben bei ATTRv-Amyloidose mit Polyneuropathie verl\u00e4ngern.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\",\"width\":880,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/startseite\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/\",\"name\":\"Amyloidosis Alliance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#organization\",\"name\":\"Amyloidosis Alliance\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"width\":252,\"height\":252,\"caption\":\"Amyloidosis Alliance\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmyloidosisAlliance\\\/\",\"https:\\\/\\\/x.com\\\/amyloidosisa\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht","description":"Eine Studie mit 201 Patienten \u00fcber drei Jahrzehnte legt nahe, dass krankheitsmodifizierende Therapien das \u00dcberleben bei ATTRv-Amyloidose mit Polyneuropathie verl\u00e4ngern.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/","og_locale":"de_DE","og_type":"article","og_title":"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht","og_description":"Eine Studie mit 201 Patienten \u00fcber drei Jahrzehnte legt nahe, dass krankheitsmodifizierende Therapien das \u00dcberleben bei ATTRv-Amyloidose mit Polyneuropathie verl\u00e4ngern.","og_url":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/","og_site_name":"Amyloidosis Alliance","article_publisher":"https:\/\/www.facebook.com\/AmyloidosisAlliance\/","article_published_time":"2024-05-01T07:20:17+00:00","article_modified_time":"2026-11-03T09:16:38+00:00","og_image":[{"width":880,"height":500,"url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_creator":"@amyloidosisa","twitter_site":"@amyloidosisa","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/#article","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/"},"author":{"name":"Amyloidosis Alliance","@id":"https:\/\/www.amyloidosisalliance.org\/de\/#organization"},"headline":"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht","datePublished":"2024-05-01T07:20:17+00:00","dateModified":"2026-11-03T09:16:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/#organization"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/","url":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/","name":"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/#primaryimage"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","datePublished":"2024-05-01T07:20:17+00:00","dateModified":"2026-11-03T09:16:38+00:00","description":"Eine Studie mit 201 Patienten \u00fcber drei Jahrzehnte legt nahe, dass krankheitsmodifizierende Therapien das \u00dcberleben bei ATTRv-Amyloidose mit Polyneuropathie verl\u00e4ngern.","breadcrumb":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/#primaryimage","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","width":880,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/www.amyloidosisalliance.org\/de\/neue-studie-zur-hereditaeren-transthyretin-amyloid-polyneuropathie-veroeffentlicht\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.amyloidosisalliance.org\/de\/startseite\/"},{"@type":"ListItem","position":2,"name":"Neue Studie zur heredit\u00e4ren Transthyretin-Amyloid-Polyneuropathie ver\u00f6ffentlicht"}]},{"@type":"WebSite","@id":"https:\/\/www.amyloidosisalliance.org\/de\/#website","url":"https:\/\/www.amyloidosisalliance.org\/de\/","name":"Amyloidosis Alliance","description":"","publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.amyloidosisalliance.org\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.amyloidosisalliance.org\/de\/#organization","name":"Amyloidosis Alliance","url":"https:\/\/www.amyloidosisalliance.org\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.amyloidosisalliance.org\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","width":252,"height":252,"caption":"Amyloidosis Alliance"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmyloidosisAlliance\/","https:\/\/x.com\/amyloidosisa"]}]}},"_links":{"self":[{"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/posts\/3945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/comments?post=3945"}],"version-history":[{"count":1,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/posts\/3945\/revisions"}],"predecessor-version":[{"id":3947,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/posts\/3945\/revisions\/3947"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/media\/3946"}],"wp:attachment":[{"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/media?parent=3945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/categories?post=3945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/tags?post=3945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}